TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3606928
Drug: 5000 units
Normalized name: A-25, 25000 units oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 units heparin
Study: 31991063
Drug: Decongesting therapy
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongesting therapy guided by ultrasound assessment of the IVC in addition to clinical assessment
Study: 29331711
Drug: Omega-3 supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplements (638mg DHA and 772mg EPA per day)
Study: 27474214
Drug: Control group;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group; evidence-based dietetic advice with 6 monthly nurse follow-up
Study: 24717368
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of 12 oz (355 mL)/d SSB (equivalent to 1 can of soda per day)
Study: 18464224
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid and long acting‐b‐agonists (LABA) combination therapy
Study: 18464224
Drug: Long-term combined
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term combined therapy with inhaled corticosteroid and LABA
Study: 18464224
Drug: Combination inhalers
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhalers (LABA and CS)
Study: 17059771
Drug: GEL (4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEL (4% succinylated gelatin)
Study: 17059771
Drug: RL (lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: RL (lactated Ringer's solution)
Study: 8841214
Drug: Endocervical 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocervical 0.5 mg of PGE2 gel
Study: 1517923
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IVIG) therapy (500 mg/kg)
Study: 1517923
Drug: Albumin treatment
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin treatment (5 mg/kg)
Study: 30700116
Drug: Short-TXA (three-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-TXA (three-hour two-dose regimen)
Study: 30700116
Drug: Long-TXA (11-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-TXA (11-hour four-dose regimen)
Study: 17463460
Drug: Drug intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug intervention to prevent diabetes (specific drug not mentioned)
Study: 15045169
Drug: Systematic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systematic administration of the Bloomsbury Sedation Score and the Glasgow Coma Scale
Study: 15045169
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of sedative drugs during weaning, timely extubation, increased surveillance
Study: 12194393
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml 0.5 mg neostigmine
Study: 12194393
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml normal saline
Study: 8602376
Drug: zidovudine 600
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine 600 mg/day alone
Study: 8602376
Drug: zidovudine with
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine with cimetidine 1200 mg/day
Study: 8602376
Drug: zidovudine with
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine with ranitidine 300 mg/day
Study: 319269
Drug: Ephedrine sulfate
Normalized name: Ephedrine Sulfate
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine sulfate and theophylline combination
Study: 31325161
Drug: Subcutaneous somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous somatostatin (22 µg/kg)
Study: 31325161
Drug: Intravenous somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous somatostatin (22 µg/kg)
Study: 27873023
Drug: Acetylcysteine (AC)
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcysteine (AC) 3 × 100 mg for 3 weeks
Study: 27873023
Drug: Azithromycin (AZ)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZ) body weight adjusted dose for 3 days
Study: 27873023
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Acetylcysteine and Azithromycin at described doses
Study: 18071727
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (prednisone, aspirin, progesterone)
Study: 18071727
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment vs Enoxaparin
Study: 18071727
Drug: Treated groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated groups (Enoxaparin and Combination)
Study: 9075507
Drug: Lignocaine 300
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 300 mg alone
Study: 9075507
Drug: Lignocaine 300
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 300 mg with fentanyl 100 micrograms
Study: 9075507
Drug: Lignocaine 200
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 200 mg with fentanyl 100 micrograms
Study: 7924831
Drug: Antioxidants (cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (cocktail of several antioxidants at high dosage)
Study: 7924831
Drug: Lymphocyte photopheresis
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphocyte photopheresis (treatment of lymphocytes with methoxypsoralen and UVA irradiation)
Study: 3555054
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg twice daily for seven days)
Study: 3555054
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily for seven days)
Study: 28189366
Drug: ECP002A (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECP002A (oral formulation of Δ9-tetrahydrocannabinol)
Study: 27942550
Drug: Palifermin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin (60 μg/kg/day as an intravenous bolus once daily for 3 days before and 3 days after chemotherapy)
Study: 27942550
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthwash (once daily for 3 days before and 3 days after chemotherapy)
Study: 24148140
Drug: Interventions designed
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventions designed to link those with SUDs to treatment
Study: 20233982
Drug: Pharmacist-assisted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-assisted medication reconciliation, inpatient pharmacist counseling, low-literacy adherence aids, and tailored telephone follow-up after discharge
Study: 18397986
Drug: Sulfonylurea (SU)
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea (SU) treatment
Study: 11004361
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus amnioinfusion (500 mL over 30 minutes, repeated if necessary)
Study: 11004361
Drug: Continuous amnioinfusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous amnioinfusion (500 mL over 30 minutes, then 3 mL per minute until delivery)
Study: 1350596
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS and beta-blocker combination
Study: 6364879
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg oral administration)
Study: 30016193
Drug: Pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd:YAG laser (high-intensity laser therapy) with exercise program, 600 J in two phases and 15 J to 10 points for a total of 750 J for each knee, thrice per week for 4 weeks.
Study: 30016193
Drug: Pulsed Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Nd:YAG laser (high-intensity laser therapy) with exercise program, thrice per week for 4 weeks.
Study: 27959716
Drug: Celecoxib (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (mean daily dose: 209±37 mg)
Study: 27959716
Drug: Naproxen (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (mean daily dose: 852±103 mg)
Study: 27959716
Drug: Ibuprofen (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (mean daily dose: 2045±246 mg)
Study: 27959716
Drug: Celecoxib (on-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (on-treatment analysis)
Study: 27959716
Drug: Naproxen (on-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (on-treatment analysis)
Study: 27959716
Drug: Ibuprofen (on-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (on-treatment analysis)
Study: 24343476
Drug: Aripiprazole (3.22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (3.22 mg/day)
Study: 24343476
Drug: Risperidone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.6 mg/day)
Study: 22499474
Drug: Weekly EBP-structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly EBP-structured case conference (Group A)
Study: 10643545
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 mg for seven opioid-naïve patients and 3.75 mg for two patients on top of their regular oral dose of 7.5 mg q4 h)
Study: 21332799
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g eicosapentaenoic acid (EPA) and 1.1 g docosahexaenoic acid (DHA) supplementation
Study: 19125875
Drug: Dexamethasone +
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone + intravenous metoclopramide + diphenhydramine
Study: 19125875
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + intravenous metoclopramide + diphenhydramine
Study: 17223212
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) infusion at 2 ml/kg body weight per hour for 12 hours
Study: 15321001
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin via AERx iDMS
Study: 31596802
Drug: Multimodal surgical-site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal surgical-site injection (ropivacaine 200 mg, epinephrine 0.6 mg, and morphine 5 mg)
Study: 28329334
Drug: DRV 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV 800 mg QD
Study: 28329334
Drug: DRV 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV 600 mg BID
Study: 18043700
Drug: Multivitamin (MV)
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multivitamin (MV) tablet
Study: 9535242
Drug: 25 microg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg/ml vancomycin added to PN
Study: 29768414
Drug: Low-dose autologous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose autologous AdMSC (1x10^6 cells/kg)
Study: 29768414
Drug: High-dose autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose autologous AdMSC (4x10^6 cells/kg)
Study: 24278924
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed at the bone level (Group 0)
Study: 24278924
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed 1 mm below the alveolar crest (Group 1)
Study: 24278924
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed 2 mm below the alveolar crest (Group 2)
Study: 24278924
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in groups 1 and 2 compared to Group 0
Study: 21929307
Drug: Chemotherapy (fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (fludarabine and cyclophosphamide without rituximab)
Study: 19099859
Drug: Carvedilol plus
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol plus traditional regimen (digoxin, prednisone and/or diuretics)
Study: 19099859
Drug: Traditional regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional regimen (digoxin, prednisone and/or diuretics)
Study: 11841719
Drug: Morphine-Adcon-L (M-ADL)
Normalized name: morphine sulfate Extended Release Oral Capsule [M-Eslon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-Adcon-L (M-ADL)
Study: 8087777
Drug: Data collection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection on current medications
Study: 578772
Drug: Etozolin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etozolin (400 mg)
Study: 578772
Drug: Etozolin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etozolin (1200 mg)
Study: 578772
Drug: Vs (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vs (75 mg)
Study: 27896440
Drug: Treosulfan intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan intravenous (i.v.) 7000 mg/m2 d1 q4w
Study: 27896440
Drug: Treosulfan oral
Normalized name: treosulfan Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan oral (p.o.) 600 mg/m2 d1-28 q8w
Study: 27896440
Drug: Treosulfan intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan intravenous (i.v.)
Study: 27896440
Drug: Treosulfan oral
Normalized name: treosulfan Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan oral (p.o.)
Study: 23417891
Drug: Taurolidine solution
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine solution
Study: 23417891
Drug: Heparin solution
Normalized name: heparin Injectable Solution
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin solution
Study: 23417891
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (Heparin)
Study: 9155592
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (240 mg)
Study: 8292702
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg/kg (after halothane and isoflurane)
Study: 29894374
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction intervention; 20 weekly, 1.5-hour sessions
Study: 27770787
Drug: Optimized virgin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized virgin olive oil with high phenolic content (OVOO, 429 mg/Kg)
Study: 27770787
Drug: Functional olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional olive oil (FOO, 429 mg/Kg phenolic compounds, 389 mg/Kg triterpenic acids)
Study: 24430787
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention and treatment with voglibose or nateglinide
Study: 12582226
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - standard behavioral weight loss program with 14 weekly sessions
Study: 10852458
Drug: Cabergoline (CAB)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (CAB) treatment at doses ranging from 0.25-3.5 mg weekly for 1-3 years
Study: 10852458
Drug: Cabergoline (CAB)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (CAB) treatment at doses ranging from 0.25-1 mg weekly for 1-6 months
Study: 10852458
Drug: Cabergoline (CAB)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (CAB) treatment at doses ranging from 1-2 mg weekly for 6-12 months and 3-3.5 mg weekly for 18-24 months
Study: 10852458
Drug: Cabergoline (CAB)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (CAB) treatment at doses ranging from 1-2 mg weekly for 1-6 months and 3 mg weekly for 12 months
Study: 9356099
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infused intravenously at a rate of 0.3 g/kg
Study: 9356099
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) infused intravenously at a rate of 5 g/kg
Study: 8449049
Drug: Albuterol by
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol by nebulizer plus placebo by inhaler (n = 20)
Study: 8449049
Drug: Albuterol by
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol by inhaler plus placebo by nebulizer (n = 15)
Study: 29873864
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy (personalized oral hygiene instructions, subgingival scaling, and root planing per quadrant)
Study: 29873864
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received equal treatment after the study period)
Study: 11823390
Drug: Intravenous nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalbuphine and propacetamol (NP)
Study: 10065346
Drug: Sustained-release lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release lithium carbonate (HP matrix)
Study: 10065346
Drug: Sustained-release lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release lithium carbonate (L matrix)
Study: 7668664
Drug: Clarion cochlear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarion cochlear implant
Study: 7668664
Drug: Nucleus implant
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus implant
Study: 6777233
Drug: Intravenous hyperalimentation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hyperalimentation (IVH) with total bowel rest
Study: 6777233
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prednisone 40 mg/day)
Study: 21868730
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg recombinant tissue-type plasminogen activator (rtPA)
Study: 19154802
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (EM) 600 mg/day, n=18
Study: 17356094
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg bid of nebulized recombinant human deoxyribonuclease (rhDNase)
Study: 11106230
Drug: XR9576 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR9576 2.0 mg/kg i.v.
Study: 11106230
Drug: XR9576 >
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR9576 > or = 200 mg/volunteer p.o.
Study: 11106230
Drug: XR9576 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR9576 (various doses)
Study: 8443849
Drug: Nasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal ketamine 6 mg.kg‐1
Study: 8443849
Drug: Promethazine and
Normalized name: Promethazine and Phenylephrine Hydrochloride Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine and meperidine 1 mg.kg‐1 each (Control)
Study: 30629148
Drug: All PAMVAC
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All PAMVAC formulations
Study: 28110412
Drug: KDIGO bundle
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KDIGO bundle (optimization of volume status and hemodynamics, avoidance of nephrotoxic drugs, preventing hyperglycemia)
Study: 15079128
Drug: Chemotherapy (31
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (31 patients)
Study: 15079128
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment (overall)
Study: 15079128
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (overall)
Study: 11463561
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cisplatin 100 mg/m² on day 1 and etoposide 120 mg/m² on days 1-3 for six cycles)
Study: 12526358
Drug: Traditional combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional combined therapy with a predominance of balanced solution
Study: 8070497
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of the ACE inhibitor perindoprilat
Study: 29420063
Drug: Random spice
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random spice isolates producing enterotoxin at levels of 4 to 16 ng/mL
Study: 26139307
Drug: Golimumab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (50 mg subcutaneously every 4 weeks)
Study: 11453957
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, average daily dose 2.4 IU (SD 0.86)
Study: 9209724
Drug: Continuing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing treatment